Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 26 clinical trials
Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia

clinical efficacy and economic impact of early step-down to oral antibiotics (within 72 hours from index blood culture collection) versus continuing standard of care IV therapy (for at least another 24

  • 04 Oct, 2022
  • 1 location
Hydrochloric Acid Lock Therapy in Children With Cancer

enrolled within 48 hours after detection of a positive blood culture/CLABSI. They will be randomized as followed: Intervention group: HALT. Control group: Normal saline (placebo

  • 13 Jul, 2022
  • 1 location
Candida PCR Diagnosis Strategy in Patients From Intensive Care Units (CANDI-PCR)

The aim of this study is to evaluate the implementation of a new technique for invasive candidiasis diagnosis by PCR. The main objective will be to evaluate the effect of this strategy on the time required to obtain results in patients from intensive care units with suspected systemic invasive candidiasis. …

  • 04 Oct, 2022
  • 1 location
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia (SHORTEN2)

Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P. aeruginosa (BSI-PA).

  • 09 Jun, 2022
  • 1 location
A Multicenter Non-inferiority Randomized Trial Comparing Cloxacillin Versus Cefazolin Efficacy for the Treatment of Bacteremia Caused by Methicillin-susceptible Staphylococcus Aureus (MSSA) (CLOCEBA)

"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%. Anti-staphylococcal penicillins (APs) such as oxacillin or cloxacillin are recommended as first-line agents. With the exception of first-generation cephalosporin (1GC) such as cefazolin, no alternative has yet proven …

  • 24 Oct, 2022
  • 1 location
Evalution of the Efficacy and Safety of Hemoperfusion Use With Polymyxin B un Patients With Severe Endotoxemia With Multiple Organ Dysfunction Syndrome After Complicated Operations With Cardiopulmonary Bypass (РМХ vs SS)

Sepsis is a state of multiple organ dysfunction caused by a generalized immune-inflammatory response of the body to an infectious agent, with pronounced heterogeneity and interchangeability of clinical and laboratory manifestations. Violation of autoregulation and multiple organ dysfunctions in case of not timely started and / or ineffective therapy lead …

  • 13 Oct, 2022
NICU Antibiotics and Outcomes Trial (NANO)

The goal of the NANO trial is to study the longstanding clinical practice of empirically administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the first days of life. In this 802-subject multicenter placebo-controlled randomized clinical trial, the hypothesis to be tested is that the incidence of adverse outcomes …

  • 04 Oct, 2022
  • 13 locations
Early Diagnosis of Native and Device-associated Meningitis

Device-associated meningitis is a severe complication after implantation of various central nervous system (CNS) devices such as ventriculoperitoneal (VP) and ventriculoatrial (VA) shunts, external ventricular drains (EVD), lumbar drains (ELD) and intrathecal pumps. In contrast to native meningitis, these infections are hard to diagnose both clinically and on the laboratory …

  • 14 Dec, 2021
  • 2 locations
Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution as an adjuctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI). Approximately …

antibiotic lock therapy
ethanol solution
antibiotic therapy
  • 06 May, 2022
  • 19 locations
Bacteremia From Periodontal Treatment to Elucidate the Underpinnings of Sepsis

Approximately 40,000 Swedes suffer from sepsiseach year, about 20% die. Biomarkers that are sensitive to current or previous bacteremia are needed in the treatment of sepsis. Bacteremia from periodontal treatment is predictive and occurs in 13-75%. The study's hypothesis is to utilize bacteremia from periodontal treatment to evaluate biological markers …

Accepts healthy volunteers
antimicrobial agent
  • 19 Apr, 2022
  • 1 location